Vericel Overview

  • Year Founded
  • 1989

Year Founded

  • Status
  • Public

  • Employees
  • 398

Employees

  • Stock Symbol
  • VCEL

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $57.53
  • (As of Friday Closing)

Vericel General Information

Description

Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.

Contact Information

Website
www.vcel.com
Formerly Known As
Aastrom Bio, Aastrom Biosciences
Ownership Status
Publicly Held
Financing Status
Formerly PE-Backed
Corporate Office
  • 25 Blue Sky Drive
  • Burlington, MA 01803
  • United States
+1 (617)
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Stock Exchange
NAS
Vertical(s)
Corporate Office
  • 25 Blue Sky Drive
  • Burlington, MA 01803
  • United States
+1 (617)

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vericel Stock Performance

As of 20-Nov-2026, Vericel’s stock price is $57.53. Its current market cap is $2.94B with 51M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$57.53 $58.26 $28.95 - $59.75 $2.94B 51M 664K $0.66

Vericel Financials Summary

As of 30-Sep-2026, Vericel has a trailing 12-month revenue of $324M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,985,628 1,783,797 2,705,999 1,679,194
Revenue 324,171 276,259 237,224 197,516
EBITDA 40,569 22,544 10,218 (1,768)
Net Income 33,308 16,518 10,362 (3,182)
Total Assets 517,110 487,969 432,722 353,657
Total Debt 90,689 96,369 98,966 88,043
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Vericel Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Vericel‘s full profile, request access.

Request a free trial

Vericel Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports
Biotechnology
Burlington, MA
398 As of 2025

Cleveland, OH
 

Basel, Switzerland
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Vericel Competitors (81)

One of Vericel’s 81 competitors is Athersys, a Formerly VC-backed company based in Cleveland, OH.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Athersys Formerly VC-backed Cleveland, OH
Roche Corporation Basel, Switzerland
Organogenesis Holdings Pending Transaction (M&A) Canton, MA
AB Science Formerly Accelerator/Incubator backed Paris, France
Lineage Cell Therapeutics Corporation Carlsbad, CA
You’re viewing 5 of 81 competitors. Get the full list »

Vericel Patents

Vericel Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4486231-B1 Devices for repairing cartilage defects Active 04-Mar-2022
EP-4775181-A2 Devices for repairing cartilage defects Pending 04-Mar-2022
EP-4775181-A3 Devices for repairing cartilage defects Pending 04-Mar-2022
EP-4486231-A1 Methods and devices for repairing cartilage defects Active 04-Mar-2022
ES-3080984-T3 Methods and devices for repairing cartilage defects Active 04-Mar-2022 A61B90/06
To view Vericel’s complete patent history, request access »

Vericel Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Vericel Investments & Acquisitions (2)

Vericel’s most recent deal was a Merger/Acquisition with Sanofi (Cell Therapy and Regenerative Medicine Business) for . The deal was made on 30-May-2014.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Sanofi (Cell Therapy and Regenerative Medicine Business) 30-May-2014 Merger/Acquisition Pharmaceuticals
RealBio Technology 30-Sep-2009 Early Stage VC Discovery Tools (Healthcare)
To view Vericel’s complete investments and acquisitions history, request access »

Vericel ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

30.81 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,593

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Biotechnology

Subindustry

of 431

Rank

Percentile

To view Vericel’s complete esg history, request access »

Vericel Exits (1)

Vericel’s most recent exit was on 30-Sep-2009 from RealBio Technology. The exit was categorized as with 4 buyers.

Company Name Exit Date Exit Type Exit Size Status Buyers
RealBio Technology 30-Sep-2009 Completed
  • 4 buyers
To view Vericel’s complete exits history, request access »

Vericel Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Marrow Donation Cambridge, MA 2019

Vericel FAQs

  • When was Vericel founded?

    Vericel was founded in 1989.

  • Where is Vericel headquartered?

    Vericel is headquartered in Burlington, MA.

  • What is the size of Vericel?

    Vericel has 398 total employees.

  • What industry is Vericel in?

    Vericel’s primary industry is Biotechnology.

  • Is Vericel a private or public company?

    Vericel is a Public company.

  • What is Vericel’s stock symbol?

    The ticker symbol for Vericel is VCEL.

  • What is the current stock price of Vericel?

    As of 20-Nov-2026 the stock price of Vericel is $57.53.

  • What is the current market cap of Vericel?

    The current market capitalization of Vericel is $2.94B.

  • What is Vericel’s current revenue?

    The trailing twelve month revenue for Vericel is $324M.

  • Who are Vericel’s competitors?

    Athersys, Roche, Organogenesis Holdings, AB Science, and Lineage Cell Therapeutics are some of the 81 competitors of Vericel.

  • What is Vericel’s annual earnings per share (EPS)?

    Vericel’s EPS for 12 months was $0.66.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process